Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series
We have previously developed and confirmed a pragmatic molecular classifier for endometrial cancers; ProMisE (Proactive Molecular Risk Classifier for Endometrial Cancer). Inspired by the Cancer Genome Atlas, ProMisE identifies four prognostically distinct molecular subtypes and can be applied to dia...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
07 February 2018
|
| In: |
Annals of oncology
Year: 2018, Jahrgang: 29, Heft: 5, Pages: 1180-1188 |
| ISSN: | 1569-8041 |
| DOI: | 10.1093/annonc/mdy058 |
| Online-Zugang: | Resolving-System, Volltext: https://doi.org/10.1093/annonc/mdy058 Verlag: https://academic.oup.com/annonc/article/29/5/1180/4844033 
|
| Verfasserangaben: | S. Kommoss, M.K. McConechy, F. Kommoss, S. Leung, A. Bunz, J. Magrill, H. Britton, F. Kommoss, F. Grevenkamp, A. Karnezis, W. Yang, A. Lum, B. Krämer, F. Taran, A. Staebler, S. Lax, S.Y. Brucker, D.G. Huntsman, C.B. Gilks, J.N. McAlpine, A. Talhouk |
| Zusammenfassung: | We have previously developed and confirmed a pragmatic molecular classifier for endometrial cancers; ProMisE (Proactive Molecular Risk Classifier for Endometrial Cancer). Inspired by the Cancer Genome Atlas, ProMisE identifies four prognostically distinct molecular subtypes and can be applied to diagnostic specimens (biopsy/curettings) enabling earlier informed decision-making. We have strictly adhered to the Institute of Medicine (IOM) guidelines for the development of genomic biomarkers, and herein present the final validation step of a locked-down classifier before clinical application. |
|---|---|
| Beschreibung: | Gesehen am 16.12.2019 |
| Beschreibung: | Online Resource |
| ISSN: | 1569-8041 |
| DOI: | 10.1093/annonc/mdy058 |